Drug Trial Radar · NCT07104383
VK2735 for Weight Management Type 2 Diabetes Phase 3 (VANQUISH 2)
Last checked: Nov 19, 2026Latest source record: Apr 7, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
1,100
Planned (sponsor's estimate)
Start
Jun 23, 2025
Primary completion
Jul 1, 2027
Study completion Aug 1, 2027
Sponsor
- Lead sponsor
- Viking Therapeutics, Inc.Industry
- Sponsor type
- Industry
- First posted
- Aug 5, 2025
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Triple (participant, care provider, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a phase 3, multicenter, 78-week randomized, double-blind, placebo-controlled, parallel arm study that will evaluate the weight loss efficacy as well as safety, tolerability, pharmacodynamic effects, and pharmacokinetics of VK2735 in adults with Type 2 Diabetes who are obese or overweight
Conditions
- Weight Loss
Interventions
VK2735Drug
VK2735 is a peptide GLP-1 and GIP dual agonist administered Once Weekly
Primary outcomes
What the sponsor says the trial is designed to measure.
- Percent change in body weight from baseline to Week 78 in body weightTime frame: 78 Weeks
Locations
127 sites in 2 countries. Site status is shown where the registry gives one.
Viking Clinical Site #2037
Birmingham, Alabama
Viking Clinical Site #2064
Birmingham, Alabama
Viking Clinical Site #2128
Huntsville, Alabama
Viking Clinical Site #2005
Chandler, Arizona
Viking Clinical Site #2017
Flagstaff, Arizona
Viking Clinical Site #2018
Peoria, Arizona
Viking Clinical Site #2135
Scottsdale, Arizona
Viking Clinical Site #2019
Tucson, Arizona
Viking Clinical Site #2036
Little Rock, Arkansas
Viking Clinical Site #2071
Chula Vista, California
Viking Clinical Site #2070
Escondido, California
Viking Clinical Site #2054
Huntington Park, California
Viking Clinical Site #2014
Lake Forest, California
Viking Clinical Site #2129
Lemon Grove, California
Viking Clinical Site #2051
Lincoln, California
Viking Clinical Site #2050
Long Beach, California
Viking Clinical Site #2078
Manteca, California
Viking Clinical Site #2053
Montclair, California
Viking Clinical Site #2068
Panorama City, California
Viking Clinical Site #2132
Rolling Hills Estates, California
Viking Clinical Site #2131
San Diego, California
Viking Clinical Site #2052
Spring Valley, California
Viking Clinical Site #2109
Tustin, California
Viking Clinical Site #2067
Van Nuys, California
Viking Clinical Site #2079
Walnut Creek, California
Viking Clinical Site #2119
Denver, Colorado
Viking Clinical Site #2013
Clearwater, Florida
Viking Clinical Site #2121
Clearwater, Florida
Viking Clinical Site #2003
Cooper City, Florida
Viking Clinical Site #2112
DeLand, Florida
Viking Clinical Site #2107
Delray Beach, Florida
Viking Clinical Site #2083
Fort Myers, Florida
Viking Clinical Site #2058
Jacksonville, Florida
Viking Clinical Site #2076
Lakeland, Florida
Viking Clinical Site #2060
Lakewood Rch, Florida
Viking Clinical Site #2117
Miami, Florida
Viking Clinical Site #2012
Ocoee, Florida
Viking Clinical Site #2056
Palmetto Bay, Florida
Viking Clinical Site #2011
Port Orange, Florida
Viking Clinical Site #2057
West Palm Beach, Florida
Showing 40 of 127 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.